Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

UC208

Sigma-Aldrich

6-Hydroxywarfarin

Sinônimo(s):

3-(α-Acetonylbenzyl)-4,6-dihydrocoumarin, 4-6-Dihydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C19H16O5
Número CAS:
Peso molecular:
324.33
Número MDL:
Código UNSPSC:
12161501
ID de substância PubChem:

cor

white

pf

119-120 °C

solubilidade

DMSO: soluble

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CC(=O)CC(c1ccccc1)C2=C(O)c3cc(O)ccc3OC2=O

InChI

1S/C19H16O5/c1-11(20)9-14(12-5-3-2-4-6-12)17-18(22)15-10-13(21)7-8-16(15)24-19(17)23/h2-8,10,14,21-22H,9H2,1H3

chave InChI

IQWPEJBUOJQPDE-UHFFFAOYSA-N

Ações bioquímicas/fisiológicas

CYP1A2/2C9 metabolite of (R)-warfarin

Embalagem

Bottomless glass bottle. Contents are inside inserted fused cone.

Nota de preparo

6-Hydroxywarfarin is soluble in DMSO.

Pictogramas

CorrosionExclamation mark

Palavra indicadora

Danger

Frases de perigo

Classificações de perigo

Acute Tox. 4 Oral - Eye Dam. 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

A E Rettie et al.
Chemical research in toxicology, 5(1), 54-59 (1992-01-01)
Previous kinetic studies have identified a high-affinity (S)-warfarin 7-hydroxylase present in human liver microsomes which appears to be responsible for the termination of warfarin's biological activity. Inhibition of the formation of (S)-7-hydroxywarfarin, the inactive, major metabolite of racemic warfarin in
Abdul Naveed Shaik et al.
Journal of pharmaceutical sciences, 105(6), 1976-1986 (2016-04-23)
The anticoagulant drug warfarin and the lipid-lowering statin drugs are commonly co-administered to patients with cardiovascular diseases. Clinically significant drug-drug interactions (DDIs) between these drugs have been recognized through case studies for many years, but the biochemical mechanisms causing these
Steven Lane et al.
British journal of clinical pharmacology, 73(1), 66-76 (2011-06-23)
Warfarin is a drug with a narrow therapeutic index and large interindividual variability in daily dosing requirements. Patients commencing warfarin treatment are at risk of bleeding due to excessive anticoagulation caused by overdosing. The interindividual variability in dose requirements is
Stacie M Bratton et al.
The Journal of pharmacology and experimental therapeutics, 340(1), 46-55 (2011-10-06)
Coumadin (R-, S-warfarin) is a challenging drug to accurately dose, both initially and for maintenance, because of its narrow therapeutic range and wide interpatient variability and is typically administered as a racemic (Rac) mixture, which complicates the biotransformation pathways. The
Development of a method for the analysis of warfarin and metabolites in plasma and urine.
J X de Vries et al.
American clinical laboratory, 14(7), 20-21 (1995-06-07)

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica